Login to Your Account



Search

Search results

Pharma: Clinic roundup

Sanofi Pasteur, the vaccines division of Sanofi SA , of Paris, said the first of two pivotal phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint. The study showed a reduction of 56 percent of dengue ...

BioWorld Today - Staff - 2014-04-29 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Teva Pharmaceutical Industries Ltd. , of Jerusalem, said it enrolled the first patient in the Pride-HD study, a phase II trial designed to evaluate the impact of pridopidine, an oral, small molecule, on motor impairment in patients with Huntington's ...

BioWorld Today - Staff - 2014-04-25 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Eisai Co. Ltd. , of Tokyo, reported that Zonegran (zonisamide) was well tolerated and efficacious when used as an adjunctive treatment for partial epilepsy, with or without secondary generalization, in children between the ages of 6 and 17 for at lea ...

BioWorld Today - Staff - 2014-04-23 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• A.P. Pharma Inc. , of Redwood City, Calif., reported additional data from a Phase III trial of APF530, for chemotherapy-induced nausea and vomiting. (BioWorld-Today-2012-07-02) ...

BioWorld Today - Staff - 2012-07-02 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Abbvie Inc. , of North Chicago, initiated a global phase III trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC). (B ...

BioWorld Today - Staff - 2014-04-16 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Galleon Pharmaceuticals Inc. , of Horsham, Pa., said its drug candidate GAL-021 was safe and well tolerated in a Phase I trial in 30 healthy adults. The company is investigating GAL-021 for improving breathing in patients receiving opioids, w ...

BioWorld Today - Staff - 2012-05-08 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Dompe Group , of Milan, said it started a phase Ib/II study to assess the safety and potential efficacy of recombinant human nerve growth factor (rhNGF) eye drops in two doses vs. placebo. (BioWorld-Today-2014-04-04) ...

BioWorld Today - Staff - 2014-04-04 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Bayer HealthCare Pharmaceuticals Inc. , of Whippany, N.J., began enrollment in a trial studying Xofigo (radium Ra 223 dichloride) injection in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mil ...

BioWorld Today - Staff - 2014-04-03 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Forest Laboratories Inc ., of New York, and Gedeon Richter Plc , of Budapest, Hungary, reported positive top-line results from a global, randomized, placebo-controlled, fixed-dose, eight-week phase IIb trial evaluating the efficacy and safety of c ...

BioWorld Today - Staff - 2014-04-01 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Teva Pharmaceuticals Industries Ltd. , of Jerusalem, said data that demonstrates significant differences in biological and immunological effects between Copaxone (glatiramer acetate, GA) and a purported generic glatiramer acetate (GA), marketed in In ...

BioWorld Today - Staff - 2014-01-14 01:00 - 0 comments - 0 attachments